New ALS Treatment Sparks Yet Another Drug Pricing Debate

October 3, 2022

(Axios) – The FDA’s expedited approval of a new ALS treatment priced at $158,000 a year, has touched off another debate over balancing regulation with patient access. Why it matters: ALS, or Lou Gehrig’s disease, is a dreaded neurological condition whose victims usually die within three years of the onset of symptoms. But there’s limited evidence the newly approved drug works, or that its price is justified. (Read More)